I

Iovance Biotherapeutics

IOVA

8.16000
USD
-0.58
(-6.64%)
Market Closed
Volume
63,519
EPS
0
Div Yield
0
P/E
-6
Market Cap
3,021,480,596
Related Instruments
A
ADAP
-0.05000
(-3.79%)
1.27000 USD
AMGN
2.78
(0.84%)
335.22 USD
B
BLUE
-0.06000
(-5.26%)
1.08000 USD
C
CRSP
-2.450
(-4.28%)
54.840 USD
E
EDIT
-0.28500
(-5.26%)
5.13500 USD
F
FATE
-0.46000
(-8.61%)
4.88000 USD
GILD
0.470
(0.62%)
76.510 USD
K
KPTI
-0.06290
(-6.37%)
0.92380 USD
N
NTLA
-1.100
(-4.19%)
25.130 USD
REGN
13.14
(1.22%)
1,091.19 USD
News

Title: Iovance Biotherapeutics

Sector: Healthcare
Industry: Biotechnology
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.